{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:07:56Z","timestamp":1768266476216,"version":"3.49.0"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T00:00:00Z","timestamp":1522454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background &amp; Aims<\/jats:title><jats:p>The aim of this integrated analysis was to assess the efficacy of the once\u2010daily combination of elbasvir 50\u00a0mg and grazoprevir 100\u00a0mg, with and without ribavirin in <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 4 (<jats:styled-content style=\"fixed-case\">GT<\/jats:styled-content>4)\u2010infected participants enrolled in the Phase 2\/3 clinical programme with elbasvir\/grazoprevir.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Treatment\u2010na\u00efve and treatment\u2010experienced participants 18\u00a0years of age or older with chronic <jats:styled-content style=\"fixed-case\">HCV GT<\/jats:styled-content>4 infection and baseline <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> \u226510\u00a0000 <jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content> were included in the analysis. The analysis population was the full analysis set (<jats:styled-content style=\"fixed-case\">FAS<\/jats:styled-content>; all participants who received at least 1 dose of study medication) and a total of 155 <jats:styled-content style=\"fixed-case\">HCV GT<\/jats:styled-content>4 participants were evaluated. The primary endpoint was sustained virologic response at week 12 (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12; <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> less than the lower limit of quantitation at 12 weeks after the completion of study therapy).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, among <jats:styled-content style=\"fixed-case\">GT<\/jats:styled-content>4\u2010infected participants treated with 12 or 16\u00a0weeks of elbasvir\/grazoprevir\u00a0\u00b1\u00a0ribavirin, the <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 efficacy rates were 96.4% (107\/111) in treatment\u2010na\u00efve participants and 88.6% (39\/44) in treatment\u2010experienced participants. The <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 rates were 96.0% (97\/101) in treatment\u2010na\u00efve participants treated with 12\u00a0weeks of elbasvir\/grazoprevir and 100% (8\/8) in treatment\u2010experienced participants treated with 16\u00a0weeks of elbasvir\/grazoprevir plus ribavirin. Efficacy was not impacted by <jats:styled-content style=\"fixed-case\">GT<\/jats:styled-content>4 subtype.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The regimens of 12\u00a0weeks of elbasvir\/grazoprevir without ribavirin, and 16\u00a0weeks of elbasvir\/grazoprevir plus ribavirin, were efficacious in <jats:styled-content style=\"fixed-case\">HCV GT<\/jats:styled-content>4\u2010infected treatment\u2010na\u00efve and treatment\u2010experienced participants respectively. Baseline <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5A resistance\u2010associated substitutions did not impact the efficacy of elbasvir\/grazoprevir in <jats:styled-content style=\"fixed-case\">GT<\/jats:styled-content>4\u2010infected participants.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.13727","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T19:46:58Z","timestamp":1519242418000},"page":"1583-1591","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-0595","authenticated-orcid":false,"given":"Tarik","family":"Asselah","sequence":"first","affiliation":[{"name":"Hepatology Department AP\u2010HP University Paris Diderot INSERM UMR1149 Beaujon Hospital  Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5298-2494","authenticated-orcid":false,"given":"Hendrik","family":"Reesink","sequence":"additional","affiliation":[{"name":"Academic Medical Center of the University of Amsterdam  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Gerstoft","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-1951","authenticated-orcid":false,"given":"Victor","family":"de Ledinghen","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9pato\u2010Gastroent\u00e9rologie H\u00f4pital Haut\u2010L\u00e9v\u00eaque CHU Bordeaux  Pessac France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Pockros","sequence":"additional","affiliation":[{"name":"Scripps Clinic and Scripps Translational Science Institute  La Jolla CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Robertson","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Hwang","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Asante\u2010Appiah","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Wahl","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bach\u2010Yen","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliav","family":"Barr","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Talwani","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Serfaty","sequence":"additional","affiliation":[{"name":"Department of Hepatology Saint\u2010Antoine Hospital  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"e0144567","DOI":"10.1371\/journal.pone.0144567","article-title":"The seroprevalence of hepatitis C antibodies in immigrants and refugees from intermediate and high endemic countries: a systematic review and meta\u2010analysis","volume":"10","author":"Greenaway C","year":"2015","journal-title":"PLoS ONE"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.11.016"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007193"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23384"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23657"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv379"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2015.07.013"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0396-4"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.09.008"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168713"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12620"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7085"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00324-12"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201300343"},{"key":"e_1_2_9_19_1","first-page":"236A","article-title":"A combination containing MK\u20105172 (HCV NS3 protease inhibitor) and MK\u20108742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in vitro in HCV replicons","volume":"56","author":"Lahser F","year":"2012","journal-title":"Hepatology"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml300017p"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00363-17"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61795-5"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00114-9"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0785"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61793-1"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.01.050"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30974-0"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0816"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"S753","DOI":"10.1016\/S0168-8278(16)01468-9","article-title":"SAT\u2010128 \u2010 C\u2010EDGE IBLD: efficacy and safety of elbasvir\/grazoprevir (EBR\/GZR) in subjects with chronic hepatitis C virus infection and inherited blood disorders","volume":"64","author":"Hezode C","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_9_30_1","first-page":"41A","article-title":"Efficacy and safety of elbasvir\/grazoprevir in treatment\u2010naive subjects with chronic HCV GT 1, GT 4 and GT 6 infection (C\u2010CORAL): a phase III randomized multinational clinical trial","volume":"63","author":"George J","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.09.045"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.050"},{"key":"e_1_2_9_33_1","unstructured":"US FDAFull Prescribing Information for ZEPATIER\u2122(elbasvir and grazoprevir) tablets for oral use.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208261s002lbl.pdf. Accessed May 24 2017."},{"key":"e_1_2_9_34_1","unstructured":"European Medicines Agency.Summary of Product Characterisitics ZEPATIER (elbasvir\/grazoprevir).http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004126\/WC500211235.pdf. Accessed May 24 2017."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"e_1_2_9_36_1","unstructured":"Health Canada.Product Monograph ZEPATIER (elbasvir\/grazoprevir tablets).https:\/\/pdf.hres.ca\/dpd_pm\/00038559.PDF. Accessed May 24 2017."},{"key":"e_1_2_9_37_1","unstructured":"Australia Therapeutic Goods Administration.Product Information ZEPATIER (elbasvir\/grazoprevir tablets).https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2016-PI-02468-1&d=2017052416114622483. Accessed May 24 2017."},{"key":"e_1_2_9_38_1","unstructured":"AASLD and IDSA.Recommendations for Testing Managing and Treating Hepatitis C.http:\/\/hcvguidelines.org\/sites\/default\/files\/HCV-Guidance_April_2017_a.pdf. Accessed May 24 2017."},{"key":"e_1_2_9_39_1","unstructured":"US FDAFull Prescribing Information for MAVYRET\u2122(glecaprevir and pibrentasvir) tablets for oral use.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209394s000lbl.pdf. Accessed August 9 2017."},{"issue":"1","key":"e_1_2_9_40_1","first-page":"433A","article-title":"High efficacy in patients with chronic hepatitis C virus (HCV) genotype (GT) 1b infection treatment with elbasvir\/grazoprevir for 12\u00a0weeks: an integrated analysis","volume":"63","author":"Zeuzem S","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_9_41_1","first-page":"555A","article-title":"High efficacy of the combination HCV regimen grazoprevir and elbasvir for 8 or 12\u00a0weeks with or without ribavirin in treatment\u2010naive, noncirrhotic HCV GT1b\u2010infected patients: an integrated analysis","volume":"62","author":"Serfaty L","year":"2015","journal-title":"Hepatology"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13727","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13727","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.13727","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:06:20Z","timestamp":1694390780000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,31]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/liv.13727"],"URL":"https:\/\/doi.org\/10.1111\/liv.13727","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,31]]},"assertion":[{"value":"2017-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}